In reverse total shoulder arthroplasty (RSA), surgeons predominantly use components from the same manufacturer. In certain situations, it may be advantageous to “mismatch” components. There is a lack of literature investigating outcomes following manufacturer-mismatched implants. Therefore, the purpose of this study was to evaluate the outcomes following RSA with manufacturer-mismatched implants. All primary or revision RSAs between 2013 to 2021 with manufacturer-mismatched glenoid and humeral components was performed. Data collected included demographic variables, postoperative function, and complications. Totally 85 patients underwent RSA with manufacturer-mismatched implants. Sixty-three were primary cases (74%) and 22 (26%) were revision cases. The mean age was 70.2 ± 8.8, and 20 (24%) were male. The mean follow-up was 47.8 (range: 24–114 months). In primary cases the mean ASES score was 79.1 ± 21.3, SANE score of 75 ± 25.4, and VAS pain score of 1.8 ± 2.5. For revisions, the mean ASES score was 61.2 ± 25.9, SANE score of 50 ± 31.9, and VAS pain score of 3.2 ± 2.9. These are comparable to historical controls. Fourteen (16.4%) patients sustained a postoperative complication, six (7.1%) underwent a reoperation. Our results demonstrate that manufacturer-mismatching has comparable postoperative function, complications, and reoperation rates to the reported literature. Level of evidence: III
Sogbein et al. (Mon,) studied this question.